Review



trial sequential analysis tsa  (STATA Corporation)


Bioz Verified Symbol STATA Corporation is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    STATA Corporation trial sequential analysis tsa
    Trial sequential analysis <t>(TSA)</t> of progression-free survival (PFS) and overall survival (OS) <t>after</t> <t>anti-CD38</t> mAbs therapy for RRMM. (A) PFS; (B) OS. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Heterogeneity-adjusted required information size to demonstrate or reject 15% relative risk ( a priori estimate) of mortality risk (with alpha of 5% and beta of 20%) is 2388 patients for PFS and 2653 patients for OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.
    Trial Sequential Analysis Tsa, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 36112 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trial+sequential+analysis+tsa/pmc10746851-132-15-20?v=STATA+Corporation
    Average 99 stars, based on 36112 article reviews
    trial sequential analysis tsa - by Bioz Stars, 2026-07
    99/100 stars

    Images

    1) Product Images from "Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials"

    Article Title: Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials

    Journal: Frontiers in Oncology

    doi: 10.3389/fonc.2023.1240318

    Trial sequential analysis (TSA) of progression-free survival (PFS) and overall survival (OS) after anti-CD38 mAbs therapy for RRMM. (A) PFS; (B) OS. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Heterogeneity-adjusted required information size to demonstrate or reject 15% relative risk ( a priori estimate) of mortality risk (with alpha of 5% and beta of 20%) is 2388 patients for PFS and 2653 patients for OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.
    Figure Legend Snippet: Trial sequential analysis (TSA) of progression-free survival (PFS) and overall survival (OS) after anti-CD38 mAbs therapy for RRMM. (A) PFS; (B) OS. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Heterogeneity-adjusted required information size to demonstrate or reject 15% relative risk ( a priori estimate) of mortality risk (with alpha of 5% and beta of 20%) is 2388 patients for PFS and 2653 patients for OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.

    Techniques Used:



    Similar Products

    trial sequential analysis tsa  (STATA Corporation)
    99
    STATA Corporation trial sequential analysis tsa
    Trial sequential analysis <t>(TSA)</t> of progression-free survival (PFS) and overall survival (OS) <t>after</t> <t>anti-CD38</t> mAbs therapy for RRMM. (A) PFS; (B) OS. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Heterogeneity-adjusted required information size to demonstrate or reject 15% relative risk ( a priori estimate) of mortality risk (with alpha of 5% and beta of 20%) is 2388 patients for PFS and 2653 patients for OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.
    Trial Sequential Analysis Tsa, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trial+sequential+analysis+tsa/pmc10746851-132-15-20?v=STATA+Corporation
    Average 99 stars, based on 1 article reviews
    trial sequential analysis tsa - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    trial sequential analysis tsa software  (STATA Corporation)
    99
    STATA Corporation trial sequential analysis tsa software
    Trial sequential analysis <t>(TSA)</t> of progression-free survival (PFS) and overall survival (OS) <t>after</t> <t>anti-CD38</t> mAbs therapy for RRMM. (A) PFS; (B) OS. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Heterogeneity-adjusted required information size to demonstrate or reject 15% relative risk ( a priori estimate) of mortality risk (with alpha of 5% and beta of 20%) is 2388 patients for PFS and 2653 patients for OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.
    Trial Sequential Analysis Tsa Software, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trial+sequential+analysis+tsa/10__1097_slash_md__0000000000010360-3-18-14?v=STATA+Corporation
    Average 99 stars, based on 1 article reviews
    trial sequential analysis tsa software - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    trial sequential analysis (tsa)  (STATA Corporation)
    90
    STATA Corporation trial sequential analysis (tsa)
    Trial sequential analysis <t>(TSA)</t> of progression-free survival (PFS) and overall survival (OS) <t>after</t> <t>anti-CD38</t> mAbs therapy for RRMM. (A) PFS; (B) OS. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Heterogeneity-adjusted required information size to demonstrate or reject 15% relative risk ( a priori estimate) of mortality risk (with alpha of 5% and beta of 20%) is 2388 patients for PFS and 2653 patients for OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.
    Trial Sequential Analysis (Tsa), supplied by STATA Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trial+sequential+analysis+tsa/pmc06486222-892-24-16?v=STATA+Corporation
    Average 90 stars, based on 1 article reviews
    trial sequential analysis (tsa) - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Trial sequential analysis (TSA) of progression-free survival (PFS) and overall survival (OS) after anti-CD38 mAbs therapy for RRMM. (A) PFS; (B) OS. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Heterogeneity-adjusted required information size to demonstrate or reject 15% relative risk ( a priori estimate) of mortality risk (with alpha of 5% and beta of 20%) is 2388 patients for PFS and 2653 patients for OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.

    Journal: Frontiers in Oncology

    Article Title: Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials

    doi: 10.3389/fonc.2023.1240318

    Figure Lengend Snippet: Trial sequential analysis (TSA) of progression-free survival (PFS) and overall survival (OS) after anti-CD38 mAbs therapy for RRMM. (A) PFS; (B) OS. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Heterogeneity-adjusted required information size to demonstrate or reject 15% relative risk ( a priori estimate) of mortality risk (with alpha of 5% and beta of 20%) is 2388 patients for PFS and 2653 patients for OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.

    Article Snippet: To further elicit the efficacy and safety of anti-CD38 mAbs in RRMM patients, we performed trial sequential analysis (TSA) using STATA 12 and R software 4.1.2, and TSA v0.9.5.10 ( www.ctu.dk/tsa ) for HR and RR, respectively.

    Techniques: